OrsoBio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TLC-3595 / OrsoBio
NCT05665751: A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

Active, not recruiting
2
76
RoW
TLC-3595 Dose 1, TLC-3595 Dose 2, Placebo
OrsoBio, Inc
Insulin Resistance
09/24
12/24
TLC-2716 / OrsoBio
NCT06564584: Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

Recruiting
2
30
RoW
TLC-2716 Dose 1, TLC-2716 Dose 2, Placebo
OrsoBio, Inc
Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease
06/25
09/25
NCT05483998: A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

Completed
1
100
RoW
TLC-2716, Placebo
OrsoBio, Inc
Healthy Subjects
04/23
06/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TLC-3595 / OrsoBio
NCT05665751: A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

Active, not recruiting
2
76
RoW
TLC-3595 Dose 1, TLC-3595 Dose 2, Placebo
OrsoBio, Inc
Insulin Resistance
09/24
12/24
TLC-2716 / OrsoBio
NCT06564584: Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

Recruiting
2
30
RoW
TLC-2716 Dose 1, TLC-2716 Dose 2, Placebo
OrsoBio, Inc
Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease
06/25
09/25
NCT05483998: A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

Completed
1
100
RoW
TLC-2716, Placebo
OrsoBio, Inc
Healthy Subjects
04/23
06/23

Download Options